Avalo Therapeutics (AVTX) Set to Release Earnings on Thursday

Avalo Therapeutics (NASDAQ:AVTX) is expected to be announcing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Avalo Therapeutics to announce earnings of ($0.5946) per share for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Monday, November 9, 2026 at 9:30 AM ET.

Avalo Therapeutics (NASDAQ:AVTX) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.25). On average, analysts expect Avalo Therapeutics to post ($2.95) EPS for the current fiscal year and ($2.62) EPS for the next fiscal year.

Avalo Therapeutics Stock Performance

Shares of AVTX opened at $7.25 on Wednesday. The stock’s 50-day moving average is $14.28 and its two-hundred day moving average is $15.97. Avalo Therapeutics has a 12 month low of $6.53 and a 12 month high of $24.27.

Wall Street Analyst Weigh In

Several brokerages recently commented on AVTX. Wedbush dropped their target price on Avalo Therapeutics from $34.00 to $22.00 and set an “outperform” rating on the stock in a report on Friday, October 23rd. Cantor Fitzgerald reissued an “overweight” rating on shares of Avalo Therapeutics in a research report on Wednesday, September 16th. HC Wainwright cut Avalo Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, October 23rd. Weiss Ratings raised shares of Avalo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Finally, Wall Street Zen downgraded shares of Avalo Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, September 12th. Eleven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Avalo Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $37.00.

Insiders Place Their Bets

In other Avalo Therapeutics news, CFO Christopher Sullivan sold 12,394 shares of the firm’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $16.33, for a total transaction of $202,394.02. Following the completion of the transaction, the chief financial officer directly owned 39,900 shares of the company’s stock, valued at $651,567. This trade represents a 23.70% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 23,258 shares of company stock worth $395,434. 4.46% of the stock is owned by company insiders.

About Avalo Therapeutics

Avalo Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for immune-mediated and inflammatory diseases. The company’s research and development programs are intended to address conditions with significant unmet medical needs.

Avalo’s lead product candidate is AVTX-009, a fully human monoclonal antibody designed to inhibit interleukin-1 beta, an inflammatory cytokine involved in several immune-related disorders. The candidate is being evaluated for potential treatment of hidradenitis suppurativa, a chronic inflammatory skin disease, and other inflammatory conditions.

The company was formerly known as Cerecor Inc and adopted the Avalo Therapeutics name in 2021.